News | February 06, 2015

Medtronic Starts U.S. Launch of In.Pact Admiral Drug-Coated Balloon

Device offers alternative treatment for peripheral arterial disease in the upper leg

Medtronic, In.Pact Admiral DCB, PAD, U.S. launch, drug-coated balloon

February 6, 2015 — United States hospitals began using a new medical device from Medtronic plc  called the In.Pact Admiral drug-coated balloon (DCB) to treat patients with peripheral arterial disease (PAD) in the upper leg. PAD is a common cardiovascular condition that causes leg pain and increases the risk of heart attack and stroke.

Recently approved by the U.S. Food and Drug Administration (FDA), the In.Pact Admiral DCB offers patients a new therapy option that has been proven to reduce the need for costly repeat procedures that are commonly associated with other available interventional therapies.

The first uses of the new medical device following FDA approval took place at NewYork-Presbyterian Hospital/Columbia University Medical Center by William Gray, M.D.; Detroit Medical Center’s Harper Hospital in Michigan by Mahir Elder, M.D.; Yuma Regional Medical Center in Arizona by Joseph Cardenas, M.D., of the Heart Center of Yuma; and Terrebonne General Medical Center in Houma, Louisiana by Craig Walker, M.D., of Cardiovascular Institute of the South.

“As an investigator in the clinical trial that contributed to this device’s FDA approval, I have seen firsthand how well the In.Pact Admiral drug-coated balloon works as a treatment for peripheral arterial disease in the upper leg,” said Gray. “Based on the trial results, which were recently published in the journal Circulation, I see the In.Pact Admiral DCB fast becoming a first-line therapy option for patients with this condition.”

The United States launch of the device begins about a week after Medtronic completed its acquisition of Covidien.  This acquisition significantly expands Medtronic’s peripheral vascular sales force, which will facilitate access to the new device.

The device is designed to reopen arteries located in the upper leg, specifically the superficial femoral and popliteal arteries, when they have been narrowed or blocked by plaque. Once deployed in the artery, the balloon delivers a proven, safe and effective dose of the anti-restenotic drug paclitaxel to the artery walls. The drug aims to prevent the artery from narrowing again by minimizing scar tissue formation.

The DCB arm of the In.Pact SFA Trial demonstrated the lowest clinically-driven target lesion revascularization (CD-TLR) rate ever reported for an interventional treatment of PAD in the superficial femoral artery (SFA), with only 2.4 percent of patients treated with the device requiring a repeat procedure at one year, compared to one in five patients (20.6 percent) treated with percutaneous transluminal angioplasty (PTA).

The data also revealed the highest reported rates of primary patency, which measures sustained restoration of adequate blood flow through the treated segment of the artery. Based on Kaplan-Meier survival estimates for primary patency at 360 days, the data showed an 89.8 percent sustained restoration of blood flow in the DCB group compared to 66.8 percent for the PTA group. Using the trial’s protocol definition, primary patency assessed at 12 months of follow up was 82.2 percent for the DCB group and 52.4 percent for the PTA group.

Results from an interim economic analysis of the In.Pact SFA Trial revealed that treatment with the DCB is cost-effective compared to balloon angioplasty from discharge through one-year of follow-up, indicating the potential to lower overall healthcare costs over the longer term.

For more information: www.medtronic.com

Related Content

Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init